Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (Nasdaq: MCRB) said management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 10:30 a.m. ET. A live webcast will be accessible via the company’s Investors and News "Events and Presentations" page and will be available for replay after the event.
The presentation offers investors a real-time update opportunity and a post-event replay for later review.
Seres Therapeutics (Nasdaq: MCRB) reported Q3 2025 results and business updates on November 5, 2025.
Key points: $47.6M cash as of September 30, 2025; company expects to fund operations through Q2 2026. Seres is finalizing the SER-155 Phase 2 protocol for prevention of bloodstream infections in allo-HSCT, planning ~248 participants with an adaptive design and an interim analysis when ~half reach the primary endpoint; interim results are anticipated within 12 months of study start pending funding. Seres received a CARB-X grant up to $3.6M, presented new SER-155 Phase 1b post-hoc data at IDWeek 2025, and continues an investigator-sponsored trial in irEC with initial readout expected in early 2026.
Q3 operating highlights include R&D $12.6M, G&A $9.5M, and net income from continuing operations of $8.2M driven by a $27.2M gain on sale of VOWST.
Seres Therapeutics (Nasdaq: MCRB) will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and business updates.
Dial-in numbers are 800-715-9871 (domestic) or 646-307-1963 (international) using conference ID 8471287. The live webcast is available via the Investors and News section at www.serestherapeutics.com. A replay will be posted shortly after the event and archived for approximately 21 days.
Seres Therapeutics (Nasdaq: MCRB) received up to $3.6 million in non-dilutive funding from CARB-X to develop and manufacture an oral liquid formulation of SER-155 for medically vulnerable patients who cannot take capsules, including intubated ICU patients.
SER-155, developed for allo-HSCT patients, showed a 77% reduction in bacterial bloodstream infections (BSIs) versus placebo in a randomized Phase 1b study and reduced systemic antibiotic use and febrile neutropenia. The company received constructive FDA feedback on a well-powered Phase 2 design and is finalizing the clinical protocol.
Seres Therapeutics (Nasdaq: MCRB) announced new post hoc data from the SER-155 Phase 1b trial will be presented orally at IDWeek 2025 on October 20, 2025. The presentation reports differences between SER-155 and placebo in bacterial and fungal bloodstream infection (BSI) pathogens, clinical BSI outcomes, antibacterial prophylaxis use, and antimicrobial resistance patterns.
Key disclosed result: in the randomized, double-blind Phase 1b cohort, SER-155 reduced BSIs by 77% and lowered systemic antibiotic use and febrile neutropenia. The company said it received constructive FDA feedback on a well-powered Phase 2 design and is finalizing the protocol while pursuing capital to advance SER-155 and its live biotherapeutics portfolio.
Seres Therapeutics (NASDAQ:MCRB) has received constructive FDA feedback on its Phase 2 study protocol for SER-155, a breakthrough therapy-designated treatment for preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant.
The planned Phase 2 study will be placebo-controlled with 248 participants, focusing on preventing bloodstream infections through 30 days post-transplant. An interim analysis is expected within 12 months of study initiation.
To extend its cash runway into Q2 2026, Seres is implementing cost reduction measures, including a 25% workforce reduction with severance costs of $1.0-$1.4 million. The company continues seeking capital to advance the SER-155 study and its broader portfolio.
Seres Therapeutics (Nasdaq: MCRB), a live biotherapeutics company, will participate in the H.C. Wainwright Global Investment Conference in New York City. The company's management will deliver a corporate presentation on September 8, 2025 at 3:00 p.m. ET.
A webcast replay of the presentation will be accessible on the Seres website approximately two hours after the event and will remain available for 21 days.
Seres Therapeutics (NASDAQ: MCRB) reported Q2 2025 financial results and business updates. The company submitted a Phase 2 study protocol to FDA for SER-155, targeting bloodstream infection prevention in stem cell transplant patients. The planned study will enroll 248 participants with interim analysis expected within 12 months of initiation.
Key financial highlights include a net loss of $19.9 million in Q2 2025, reduced from $26.2 million in Q2 2024. The company received a $25 million payment from Nestlé Health Science in July 2025 and expects to fund operations into Q1 2026. Management changes include the appointment of Thomas DesRosier and Marella Thorell as co-CEOs, effective August 1, 2025.
Seres Therapeutics (NASDAQ: MCRB), a leading live biotherapeutics company, has scheduled its second quarter 2025 financial results and business updates conference call for August 6, 2025, at 8:30 a.m. ET.
The company will host both a conference call and live audio webcast. Investors can access the call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 3641971. The webcast will be available in the "Investors and News" section of the Seres website and will remain archived for approximately 21 days.
Seres Therapeutics (NASDAQ:MCRB) announced a significant leadership transition as Thomas DesRosier and Marella Thorell are appointed co-CEOs, effective July 31, 2025, following current CEO Eric Shaff's departure. Both executives will retain their existing roles as Chief Legal Officer and Chief Financial Officer, respectively.
The company is actively engaging with multiple parties for potential business development and partnerships to secure additional capital for advancing SER-155, which has received Breakthrough Therapy designation. The drug showed promising Phase 1b results with a 77% relative risk reduction in bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT).
Eric Shaff, who led Seres for a decade and achieved the first-ever FDA-approved oral microbiome therapy, will remain on the company's Board of Directors.